Anixa Biosciences Inc
Research Anixa Biosciences Inc (ANIX) on Bullrun: market cap USD 100.30M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANIX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 100.30M
- Financial periodQ3 2026
- RevenueUSD 0
- Net income-USD 2.61M
- Free cash flow-USD 1.77M
Valuation Snapshot
latest market cap is USD 100.30M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 10.93M | -USD 7.17M | n/a | -0.34 | USD 1.24M | USD 204.00K | USD 15.16M |
| FY2024 | USD 210.00K | -USD 12.55M | -USD 7.34M | 0.0% | -0.39 | USD 1.27M | USD 232.00K | USD 20.00M |
| FY2023 | USD 210.00K | -USD 9.81M | -USD 6.21M | 23.3% | -0.32 | USD 915.00K | USD 175.00K | USD 24.34M |
| FY2022 | USD 0 | -USD 13.60M | -USD 6.49M | n/a | 0.45 | USD 12.36M | USD 221.00K | USD 29.05M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 100.30M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 103.00M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 74.70M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 120.84M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 131.38M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 89.25M | n/a | n/a | n/a |
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Anixa Biosciences Inc's market cap?
Anixa Biosciences Inc's market capitalization is USD 100.30M.
What does Anixa Biosciences Inc do?
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.